wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38977579-48B3DA1F-67E2-43E2-9202-7D91505ED134
Q38977579-48B3DA1F-67E2-43E2-9202-7D91505ED134
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38977579-48B3DA1F-67E2-43E2-9202-7D91505ED134
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
P2860
Q38977579-48B3DA1F-67E2-43E2-9202-7D91505ED134
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38977579-48B3DA1F-67E2-43E2-9202-7D91505ED134
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e5d9401adb307d32829e95921b9c093ba055631d
P2860
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis